ARCH VENTURE MANAGEMENT LLC
Q3 2026 Form 13-F

CHICAGO, ILLINOIS
CIK 0001274403 · CRD 158196 · Exempt reporting adviser
$1.6B Reported Value Total

ARCH VENTURE PARTNERS reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-30
Reported value
$1.6B
Quarter over quarter
-8.7%
Holdings
17
Top-10 concentration
86.6%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Mark Mcdonnell
Managing Director, CFO and CAO

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $1.6B
Positions 17
Change in reported value +46.6%
New positions 7
Exited positions 2
Position turnover 47.4%
Top-10 concentration 86.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
17 $1.6B
Q2 2026 13F
Filed Aug 14, 2026
12 $1.1B
Q1 2026 13F
Filed May 15, 2026
10 $677.1M
Q4 2025 13F
Filed Feb 17, 2026
9 $651.7M
Q3 2025 13F
Filed Nov 14, 2025
9 $492.4M
Q2 2025 13F
Filed Aug 14, 2025
11 $299.1M
Q1 2025 13F
Filed May 15, 2025
9 $206.2M
Q4 2024 13F
Filed Feb 14, 2025
9 $230.2M
Q3 2024 13F
Filed Nov 14, 2024
9 $260.6M
Q2 2024 13F
Filed Aug 14, 2024
9 $266.0M
Q1 2024 13F
Filed May 15, 2024
8 $80.3M
Q4 2023 13F
Filed Feb 14, 2024
7 $163.5M
Q3 2023 13F
Filed Nov 14, 2023
7 $154.0M
Q2 2023 13F
Filed Aug 9, 2023
6 $162.0M
Q1 2023 13F
Filed May 15, 2023
8 $207.2M
Q4 2022 13F
Filed Feb 14, 2023
8 $390.4M
Q3 2022 13F
Filed Nov 10, 2022
10 $771.4M
Q2 2022 13F
Filed Aug 15, 2022
10 $820.6M
Q1 2022 13F
Filed May 13, 2022
8 $699.8M
Q4 2021 13F
Filed Feb 14, 2022
9 $945.3M

8 earlier quarters on file — choose one from the quarter menu above.

Top 17 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 KARD KARDIGAN INC $221.9M 13.75%
2 PBLS PARABILIS MEDICINES INC $207.1M 12.83%
3 VIR VIR BIOTECHNOLOGY INC $141.9M 8.8%
4 SANA SANA BIOTECHNOLOGY INC $133.7M 8.29%
5 SPTX SEAPORT THERAPEUTICS INC $127.0M 7.87%
6 RAPP RAPPORT THERAPEUTICS INC $125.3M 7.77%
7 SRRK SCHOLAR ROCK HLDG CORP $113.3M 7.03%
8 MAZE MAZE THERAPEUTICS INC $112.0M 6.94%
9 BEAM BEAM THERAPEUTICS INC $111.0M 6.88%
10 ERAS ERASCA INC $104.0M 6.44%
11 MASS 908 DEVICES INC $70.6M 4.38%
12 PRME PRIME MEDICINE INC $56.5M 3.5%
13 LYEL LYELL IMMUNOPHARMA INC $31.8M 1.97%
14 GENB GENERATE BIOMEDICINES INC $29.2M 1.81%
15 NMRA NEUMORA THERAPEUTICS INC. $20.2M 1.25%
16 BOLD BOUNDLESS BIO INC $6.8M 0.42%
17 GOSS GOSSAMER BIO INC $1.2M 0.07%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings